Respiratory and Thoracic Cancers Archives - MPR

Respiratory and Thoracic Cancers

Keytruda Gains Expanded Monotherapy Indication for First-Line Treatment of NSCLC

Merck announced that the Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 (tumor proportion score [TPS] ≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC

The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.

Higher-Volume Hospitals Have Better Laryngectomy Outcomes

Hospitals in the top-volume quintile (>28 cases per year) were associated with decreased odds of in-hospital mortality (odds ratio, 0.45), postoperative surgical complications (odds ratio, 0.63), and acute medical complications (odds ratio, 0.63).